Glenmark Life Sciences Ltd files DRHP with SEBI for IPO equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Glenmark arm files IPO papers with SEBI
April 17, 2021
Plans to sell over 73 lakh shares via Offer For Sale
Glenmark Life Sciences Limited, a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, has filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer.
The company plans to raise ₹1,160 crore with an Offer For Sale of up to 7,305,245 equity shares of ₹2 each of Glenmark Life Sciences Limited. The board of directors of Glenmark Pharmaceuticals Limitedon Friday approved the OFS.
Glenmark Pharma holds 100 per cent stake in Glenmark Life Sciences, which is primarily into manufacturing and marketing of Active Pharmaceutical Ingredients (APIs). It has a product portfolio of more than 130 APIs and a catalogue of over 270 inventions. The firm, which supplies APIs to more than 700 customers across 65 countries, also develops 10-12 new products every year. Glenmark Life Sciences has manufacturing operations in Gujara
(0)
NEW YORK, April 8, 2021 /PRNewswire/ The World Health Organization (WHO) has designated October 10
th as World Mental Health Day in order to raise awareness about such issues and lessen people s hesitation in seeking treatment. As a result of such initiatives, the global
anxiety and depression treatment market value is predicted to increase from $17,770.9 million in 2020 to $24,467.7 million by 2030, at a 3.3% CAGR between 2021 and 2030, according to the market research report published by P&S Intelligence.
Similarly, a program, named Better Outcomes in Mental Health Care (BOiMHC), and an organization, called Mental Health Association, have been formed to help the cause in Australia. Another such organization aiding the anxiety and depression treatment market growth with its support to patients and educational courses is the National Alliance on Mental Illness (NAMI), which was founded in the U.S. in 1979.
Generic Drugs Market Revenue Worth $786 Billion by 2030 says P&S Intelligence
NEW YORK, March 17, 2021 /PRNewswire/ Almost 75% of the deaths in 2020 were because of chronic diseases, as per the World Health Organization (WHO). Among the diseases, the deadliest were ischemic heart disease, diabetes, cancer, and stroke. This is to be a major factor to propel the global generic drugs market size to $786.0 billion by 2030 from $278.4 billion in 2019, at a 10.0% CAGR between 2020 and 2030. This is because branded drugs are often expensive, which is why a large number of people in developing countries are not able to purchase them.
Generic drugs, on the other hand, are cost-effective, at the same time contain the same active ingredients and have a similar effect as patented drugs. In this regard, the generic drugs market is also being driven by the patent expiry of blockbuster medications. As patented drugs lose their certification, it gives pharmaceutical companies the opportunity to
Share this article
MUMBAI, Feb. 12, 2021 /PRNewswire/
Glenmark s consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21
Consolidated EBITDA rises by 20.45% to Rs. 5300.72 Mn. in Q3 FY 2020-21
Highlights for Q3 FY 2020-21
India Business grew by 11.82% to Rs. 8,821.19 Mn.
Europe Business grew by 1.42% to Rs. 3,133.29 Mn.
US Business experienced sales decline of (2.43%) to Rs. 7,803.87 Mn.
API Business grew by 22.09% to 3,200.70 Mn.
Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the third quarter ended December 31 of the financial year 2020-21.
For the third quarter of FY 2020-21, Glenmark s consolidated sales was at Rs. 27,605.07 Mn. as against Rs. 26,574.51 Mn. recording an increase of 3.88 %.